SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Why the future of marijuana legalization remains hazy despite high public support 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
AstraZeneca plc, a British-Swedish pharmaceutical and biotechnology company, is reportedly withdrawing its COVID-19 vaccine worldwide. The company made the decision months after admitting in court there is a rare side effect.
But then again, according to Channel News Asia, AstraZeneca did not say this was the reason for the pullout of the vaccines. Rather, the company said it was due to “commercial reasons.”
Taking Back the COVID-19 Vaccines Years After Release
AstraZeneca said on Tuesday, May 7, the withdrawal of its vaccines around the world is already underway. It stressed that this is due to a "surplus of available updated vaccines" since the pandemic.
Moreover, the pharmaceutical and biotech firm announced it would also retract the vaccine Vaxzevria's marketing authorizations in Europe. AstraZeneca added that it is no longer producing its COVID-19 vaccine, so supply to the market has also stopped.
“As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines,” the company’s spokesman said in a statement. “This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.”
Reported Side Effects of Vaxzevria
AstraZeneca reportedly admitted in court documents that the vaccine has side effects like low platelet counts and blood clots. British newspapers stated that based on legal documents, the company's vaccine may cause TTS, but in very rare cases. World Health Organization (WHO), said this condition called Thrombosis with Thrombocytopenia Syndrome is a serious and life-threatening negative effect.
“It is admitted that the AZ vaccine can, in very rare cases, cause TTS,” AstraZeneca said in court documents in February. “The causal mechanism is not known.”
UK’s The Independent reported that AstraZeneca’s admission came after it was sued in the U.K. The class action lawsuits alleged that the company’s vaccine caused deaths and severe injuries, and claimants are seeking damages up to £100 million for around 50 supposed victims.
Photo by: Mufid Majnun/Unsplash
